# A Phase II Study of Paclitaxel and Carboplatin in Patients With an Elevated-Risk Cancer of the Uterus

> **NCT00584909** · PHASE2 · TERMINATED · sponsor: **University of Alabama at Birmingham** · enrollment: 13 (actual)

## Conditions studied

- Uterine Cancer

## Interventions

- **DRUG:** Paclitaxel and carboplatin combination

## Key facts

- **NCT ID:** NCT00584909
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-03
- **Primary completion:** 2010-09
- **Final completion:** 2011-09
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** low accrual
- **Last updated:** 2017-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00584909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00584909, "A Phase II Study of Paclitaxel and Carboplatin in Patients With an Elevated-Risk Cancer of the Uterus". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00584909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*